Related Experiment Video
Updated: Jun 16, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Insights
Optimizing pediatric acute leukemia therapy requires better risk stratification for acute lymphoblastic leukemia (ALL) and improved remission induction and maintenance for acute myeloid leukemia (AML). Addressing drug resistance and long-term toxicity is crucial for better outcomes.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Therapeutics
Background:
- Optimal therapy for acute leukemias in children remains a significant challenge.
- Current treatment strategies require refinement for both standard and high-risk patient groups.
Purpose of the Study:
- To identify key areas for improvement in pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) treatment.
- To highlight the need for strategies to overcome drug resistance and minimize treatment toxicity.
Main Methods:
- The abstract does not specify methods, but discusses challenges in risk stratification and treatment efficacy.
- Focuses on the clinical problems in managing pediatric leukemias.
Main Results:
- Standard-risk ALL patients have a good prognosis, necessitating therapies with minimal toxicity.
- High-risk ALL requires strategies to combat early drug resistance in lymphoblasts.
- AML remission induction needs improvement, and remission maintenance is a critical unmet need.
Conclusions:
- Further research is essential to develop more effective and less toxic therapies for childhood acute leukemias.
- Addressing drug resistance in ALL and improving remission maintenance in AML are paramount for advancing patient survival and quality of life.
Abstract:
As can be seen, there are many problems yet to be solved in the development of optimal therapy for acute leukaemia in children. For patients with ALL we must be able to identify clearly the standard and the varieties of high risk patients. For the patient with standard risk features life expectancy is long and therapy regimens must be designed to provide optimal control of the disease with minimal short and long-term toxicity. For patients with the high risk features of those varieties of ALL associated with poor prognosis methods must be found to circumvent the problem of early acquisition of drug resistance by the leukaemic lymphoblasts. For children with AML the results of remission induction regimens must still be improved to match those obtained in ALL. The major problem awaiting solution, however, is the maintenance of remission once obtained. As disease-free survival in AML is improved then consideration of CNS prophylaxis and the timing of cessation of therapy must be considered.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...